Updated:
Barinthus Biotherapeutics plc.
Barinthus Biotherapeutics plc. is a UK clinical-stage biopharmaceutical firm developing T-cell immunotherapies for infectious diseases and cancer.
Barinthus Biotherapeutics plc.
Barinthus Biotherapeutics plc., formerly known as Vaccitech plc., is a clinical-stage biopharmaceutical company based in the UK. The firm emerged from academic research at the University of Oxford's Jenner Institute, with initial operations focused on infectious disease vaccines (per the firm's official communications, 2023). Its lead candidate, VTP-300, targets chronic hepatitis B virus (public record). The company's pipeline spans infectious diseases—including hepatitis B, human papillomavirus, and prostate cancer—through immunotherapy platforms. Deployments center on clinical-stage assets, with funding raised through equity offerings and institutional partnerships. The firm maintains a UK operational base with potential additional sites (per public filings, 2024). Barinthus is publicly listed on the Nasdaq Global Select Market (symbol: BRNS) as of 2021, following its SPAC merger. The company's team size is not publicly enumerated but includes executives from Oxford spinouts and large pharma. No philanthropic structures are separately disclosed. A structural differentiator is the firm's proprietary ChAdOx1 and MVA vaccine platforms, originally developed at Oxford and used in the Oxford-AstraZeneca COVID-19 vaccine. This academic-industry pipeline gives a unique mechanism-based approach to immunotherapy (public record).
General information
Firm type
Family Office
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
Who runs investment decisions at Barinthus Biotherapeutics?
Barinthus Biotherapeutics is a publicly traded company, not a family office. Investment decisions are overseen by the board of directors, led by CEO and executives including Chief Medical Officer and R&D heads (per the firm's corporate governance filings). No single individual is disclosed as the principal decision-maker.
How does Barinthus Biotherapeutics source deals?
The firm's pipeline arises largely from its academic origins at the University of Oxford's Jenner Institute. It has in-licensed the ChAdOx1 and MVA platforms and may pursue partnerships or acquisitions, but specific deal sourcing mechanisms are not publicly detailed.
Is Barinthus Biotherapeutics structured as a family office?
No. Barinthus Biotherapeutics plc. is a clinical-stage biopharmaceutical corporation listed on Nasdaq. It operates with a conventional corporate governance structure, not as a family office or investment vehicle.
Does Barinthus Biotherapeutics invest in other companies or only direct assets?
As a biopharmaceutical developer, Barinthus focuses on internal pipeline development through clinical trials. It may engage in licensing or collaboration deals with other firms, but direct external investments are not its core activity.
What investment stages does Barinthus Biotherapeutics target?
The company is a developer of therapeutics in clinical-stage development, including Phase 1 and Phase 2 trials for chronic hepatitis B and oncology candidates. Full commercial-stage assets are not yet recorded.
Which sectors does Barinthus Biotherapeutics explicitly avoid?
Public disclosures do not list specific avoided sectors. The firm solely operates in biopharmaceutical immunotherapy within infectious diseases and oncology.
Where does the underlying wealth come from?
Barinthus Biotherapeutics is a publicly traded company, not a family office. Its capital comes from public market equity raises, institutional investors, and biotech venture funding, not private wealth.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: